Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 1.00 |
| ▸ | HCAR3 | P49019 | 2/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172516 | 0.95 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11403580 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11408463 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11231985 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11412506 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11226614 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL11222245 | 0.93 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| Hydrochloric Acid SCHEMBL11397237 | 0.92 | HCAR2 (0.97) | HCAR2HCAR3DAO | |
| SCHEMBL3999370 | 0.89 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL5600095 | 0.84 | HCAR2 (0.73) | HCAR2HCAR3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| EP-4595775-A2 | BHB-CITRATE COMBINATION PRODUCTS FOR RENAL HEALTH AND TREATING DISEASE | The Regents of the University of California (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240282454-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2024-08-22 | — | — | US | disclosed |
| EP-4366696-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | Gannex Pharma Co., Ltd. (CN) | 2024-05-15 | — | — | EP | disclosed |
| EP-4355915-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | Genfit (FR) | 2024-04-24 | — | — | EP | disclosed |
| CN-117915891-A | Combination therapy for the treatment of liver diseases | 甘莱制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-106255688-A | Morpholine pyridine derivate | 豪夫迈·罗氏有限公司 | 2016-12-21 | — | — | CN | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2011057110-A1 | GPR109A AGONISTS FOR THE TREATMENT OF CEREBRAL ISCHEMIA | RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG (DE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057110-A1 | GPR109A AGONISTS FOR THE TREATMENT OF CEREBRAL ISCHEMIA | RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG (DE) | 2011-05-12 | — | — | WO | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| CN-1575191-A | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | PYGL, GYS2, OAT | HCAR2 2051/4885HCAR3 2906/4885DAO 1953/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885DAO 1957/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885DAO 1957/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | HCAR2 870/4885HCAR3 1608/4885DAO 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.